Roger T. Anderson, PhD

Articles by Roger T. Anderson, PhD

Health System Correlates of Receipt of Radiation Therapy After Breast-Conserving Surgery: A Study of Low-Income Medicaid-Enrolled Women

ByRoger T. Anderson, PhD,Gretchen G. Kimmick, MD, MS,Fabian Camacho, MS,J. Timothy Whitmire, PhD,Carol Dickinson, CTR,Edward A. Levine, MD,Frank M. Torti, MD, MPH,Rajesh Balkrishnan, PhD

October 15th 2008

Omission of radiation therapy after breast-conserving surgery leads to poor outcomes. Geographic isolation and scarcity of healthcare specialists correlate with low adjuvant radiation therapy use.

Risk Classification of Medicare HMO Enrollee Cost Levels Using a Decision-Tree Approach

ByRoger T. Anderson, PhD,Rajesh Balkrishnan, PhD,Fabian Camacho, MS

February 1st 2004

Effect of Prescription Benefit Changes on Medical Care Utilization in a Medicare HMO Population

ByRajesh Balkrishnan, PhD,Wesley G. Byerly, PharmD,Fabian T. Camacho, MS,Anshu Shrestha, BS,Roger T. Anderson, PhD

November 1st 2001

Predictive Power of a Risk-Assessment Questionnaire Across Different Disease States: Results in an Elderly Managed Care Enrolled Population

ByRajesh Balkrishnan, PhD,Roger T. Anderson, PhD

February 1st 2001

Roger T. Anderson, PhD

Articles by Roger T. Anderson, PhD

Health System Correlates of Receipt of Radiation Therapy After Breast-Conserving Surgery: A Study of Low-Income Medicaid-Enrolled Women

Risk Classification of Medicare HMO Enrollee Cost Levels Using a Decision-Tree Approach

Effect of Prescription Benefit Changes on Medical Care Utilization in a Medicare HMO Population

Predictive Power of a Risk-Assessment Questionnaire Across Different Disease States: Results in an Elderly Managed Care Enrolled Population

Latest Updated Articles

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

New York Experts Push for Coordinated Obesity Care Teams

Grocery Assistance Benefit Linked to Fewer Diabetes Complications

Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping